Researchers study the cancer cell genes that resist drugs

September 25, 2017, RUDN University

Researchers from the People's Friendship University of Russia (RUDN University) have studied the mechanism of drug resistance for ovarian and breast cancer cells. They discovered that these cancer cells have a redox-dependent mechanism which is tasked with sustaining their drug resistance. The results have been published in two articles in the journal of Free Radical Biology and Medicine.

Researchers from the RUDN University have reported one of the reasons that chemotherapy (in particular, cisplatin) gradually stops affecting the of ovarian and breast tumors.

The authors studied the biochemical mechanisms that allow to develop resistance to antitumor drugs. During chemotherapy, certain drugs cause toxic and oxidative stress to and stop their functioning. Sometime later, however, the cells adapt to the action, which necessitates using stronger doses, which, in turn, negatively affects the patient's health due to its toxic effect.

To stop the development of , researchers need to learn how to control the expression of genes responsible for cell viability. Redox processes regulate cell antioxidant defense, which protects the cell against oxidative stress so that it can function properly. Without those "defender genes," it would be far easier for drugs to kill cancer cells. The researchers hope that the process could eventually be controlled.

Some of these changes in gene expression happen when human ovarian cancer (SKOV-3) cells and human breast cancer (MCF-7) cells develop resistance to an antitumor drug, cisplatin. The antitumor action of cisplatin is achieved in no small part by its pro-oxidant effect, meaning that it uses oxidative stress to destroy cells.

"As a result of development of the drug resistance in cancer cells, we observed an increase in the gene expression encoding isoforms of thioredoxin and peroxiredoxin, which play an important role in the antioxidant defense system and redox-dependent signaling. Significant increase in expression of such genes substantially contributes to a high level of antioxidant defense and therefore cancer cell resistance to the pro-oxidant action of cisplatin. Thus, the growth of expression of the Prx6 gene was observed in the resistant cells. The data also points to a significant role of Prx1, Prx2 and Prx3 isoforms in the redox-dependent mechanisms of the resistance development of the cell lines," says Elena Kalinina, one of the authors.

The increase in points to the fact that isoforms of thioredoxin and peroxiredoxin participate in the development of cancer cell drug resistance. The researchers note that this effect can also be considered as a part of a redox-dependent adaptive antioxidant response to the caused by cisplatin's pro-oxidant action.

"The results obtained significantly expand our fundamental knowledge of the sum total of molecular events in the mechanisms of death and formation of drug resistance for cancer cells and of the role redox-dependent systems in these processes," says Kalinina. These results could enable researchers to improve the drug treatment programs for oncology patients.

Explore further: Personalised cancer treatment

More information: Elena Kalinina et al, Thioredoxins, glutaredoxins and peroxiredoxins in redox-dependent formation of cancer cell resistance, Free Radical Biology and Medicine (2017). DOI: 10.1016/j.freeradbiomed.2017.04.137

Related Stories

Personalised cancer treatment

September 4, 2017
In Norway, more and more people are being affected by cancer of the mouth and throat. In recent years, the incidence has increased but the mortality has remained the same. Cisplatin is one of the most commonly administered ...

Researchers discover cancer stem cell pathway in endometrial cancer

August 24, 2017
A team of Cleveland Clinic researchers have discovered a key pathway that leads to recurrence and treatment resistance in endometrial cancer, providing the potential for much needed new therapies for women with limited options.

Resistance is futile: Researchers identify gene that mediates cisplatin resistance in ovarian cancer

April 15, 2013
Platinum compounds, such as cisplatin and carboplatin, induce DNA cross-linking, prohibiting DNA synthesis and repair in rapidly dividing cells. They are first line therapeutics in the treatment of many solid tumors, but ...

Combination therapy improved chemoresistance in ovarian cancer

November 1, 2016
Treating ovarian cancer with platinum-based chemotherapy drugs such as cisplatin is initially very effective, with about four out of five patients responding favorably. However, most of these patients quickly become resistant ...

Immune cells help reverse chemotherapy resistance in ovarian cancer

May 20, 2016
Inside each ovarian tumor, there are good cells and bad cells. A new paper explains their roles:

Recommended for you

Single blood test screens for eight cancer types

January 18, 2018
Johns Hopkins Kimmel Cancer Center researchers developed a single blood test that screens for eight common cancer types and helps identify the location of the cancer.

Researchers find a way to 'starve' cancer

January 18, 2018
Researchers at Vanderbilt University Medical Center (VUMC) have demonstrated for the first time that it is possible to starve a tumor and stop its growth with a newly discovered small compound that blocks uptake of the vital ...

The pill lowers ovarian cancer risk, even for smokers

January 18, 2018
(HealthDay)—It's known that use of the birth control pill is tied to lower odds for ovarian cancer, but new research shows the benefit extends to smokers or women who are obese.

These foods may up your odds for colon cancer

January 18, 2018
(HealthDay)—Chowing down on red meat, white bread and sugar-laden drinks might increase your long-term risk of colon cancer, a new study suggests.

How cancer metastasis happens: Researchers reveal a key mechanism

January 18, 2018
Cancer metastasis, the migration of cells from a primary tumor to form distant tumors in the body, can be triggered by a chronic leakage of DNA within tumor cells, according to a team led by Weill Cornell Medicine and Memorial ...

Modular gene enhancer promotes leukemia and regulates effectiveness of chemotherapy

January 18, 2018
Every day, billions of new blood cells are generated in the bone marrow. The gene Myc is known to play an important role in this process, and is also known to play a role in cancer. Scientists from the German Cancer Research ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.